Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) ~~Compounds~~ A compound having affinity to and/or selectivity for P-selectin~~, represented by the following~~ and having structure of formula Ia:



~~and their~~ or a stereo-isomer~~s~~ thereof~~,~~ represented by the following formula Ib:



wherein:

X is an optional group, which represents -O-, -OCH_2-, -S-, -SCH_2-, -NH- or -$NHCH_2$-;

R^1 represents QR^4, herein Q represents- O-, -NH-, -NH-(C=O)-, -O-(C=O), -NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R^4 represents any substituent comprising at least one carbon atom;

R^2 is a moiety bearing at least one negative charge and

R^3 ~~can be~~ is any group.

2. (currently amended) The compound~~s~~ according to claim 1, wherein X is not present or represents -O-.

3. (currently amended) The compounds according to ~~any one of the preceding claims~~ claim 1, wherein Q represents -NH-(C=O)-.

4. (currently amended) The compound~~s~~ according ~~to any one of the preceding claims~~claim 1, wherein R^2 is or comprises a phosphate group.

5. (currently amended) The compound~~s~~ according to ~~any one of tile preceding claims~~claim 1, wherein R^3 represents OH or YR^5, wherein Y is -O-, -CH_2- or -NH- and R^5 comprises at least one carbon atom.

6. (currently amended) The compound~~s~~ according to ~~any one of the preceding claims~~claim 1, wherein R^4 comprises an alkyl moiety, an aromatic moiety or a group comprising an electron withdrawing moiety.

7. (currently amended) The compound~~s~~ according to claim 6, wherein R^4 is a phenyl or a naphthalene group.

8. (currently amended) ~~Compounds~~ A compound having affinity to and/or selectivity for P-selectin, represented by the formula Ia,



~~and their~~ or a stereo-isomer~~s~~ thereof, represented by the formula Ib,



-wherein:

X is an optional group, which represents -O-, -OCH_2-, -S-, -SCH_2-, -NH- or –$NHCH_2$-;

R^1 represents QR^4, herein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O), -NH-(C=O)-O- or -NH-C=O)-NH-; and wherein R^4 represents any substituent comprising at least one carbon atom;

R^2 is a moiety bearing at least one negative charge and

R^3 ~~can be~~ is any group,

wherein R^3 comprises an anchor moiety capable of anchoring the compound to a colloidal or microparticulate drug carrier.

9. (currently amended) The compounds according to claim 8, wherein the anchor moiety is a peptide or peptidomimetic moiety having affinity to P-selectin.

10 - 13 (canceled)

14. (currently amended) ~~Pharmaceutical~~ A composition~~,~~ comprising in a pharmaceutically acceptable carrier a compound according to claim 1 ~~having affinity to and/or selectivity for P-selectin, represented by the formula Ia, and its stereo-isomer, represented by the formula Ib, wherein:~~

~~X is an optional group, which represents -O-, $-OCH_2-$, -S-, $-SCH_2-$, -NH- or $-NHCH_2-$;~~

~~R^1 represents QR^4, herein Q represents -O-, -NH-, -NH(C=O)-, -O(C=O), -NH(C=O)-O- or -NH(C=O)NH-; and wherein R^4 represents any substituent comprising at least one carbon atom;~~

~~R^2 is a moiety bearing at least one negative charge and~~

~~R^3 can be any group,~~

or a derivative, salt, conjugate, solvate, or multimer thereof

15. (currently amended) A method for determining whether a compound is capable of binding to P-selectin or a functional equivalent of P-selectin, comprising contacting and incubating the compound to be tested and a predetermined amount of a compound having affinity to and/or selectivity for P-selectin, represented by the formula Ia,



~~and its~~ or a stereo-isomer thereof~~,~~ represented by the formula Ib~~,~~.



wherein:

X is an optional group, which represents -O-, -OCH_2-, -S-, -SCH_2-, -NH- or -$NHCH_2$-;

R^1 represents QR^4, herein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O), -NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R4 represents any substituent comprising at least one carbon atom;

R2 is a moiety bearing at least one negative charge and

R' can be any group,

with a predetermined amount of P-selectin or said functional equivalent of P-selectin and

subsequently determining the amount of the same compound.

16. (new) A method of treating or inhibiting a disease or condition involving activation and/or overexpression of P-selectin in a mammal inflicted with such a disease, the method comprising administering to the mammal an effective P-selectin inhibiting amount of a composition according to claim 14.